Senti Biosciences, Inc. (NASDAQ:SNTI - Get Free Report)'s stock price fell 3% during trading on Wednesday . The stock traded as low as $3.19 and last traded at $3.21. 30,699 shares traded hands during trading, a decline of 96% from the average session volume of 802,648 shares. The stock had previously closed at $3.31.
Wall Street Analysts Forecast Growth
Separately, Chardan Capital reaffirmed a "buy" rating and set a $12.00 price objective on shares of Senti Biosciences in a research note on Friday, May 2nd.
Check Out Our Latest Stock Analysis on Senti Biosciences
Senti Biosciences Price Performance
The firm's 50 day moving average is $3.38 and its 200 day moving average is $3.80. The company has a market cap of $80.59 million, a PE ratio of -0.20 and a beta of 2.31.
Senti Biosciences (NASDAQ:SNTI - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($1.41) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.85). The firm had revenue of $1.30 million for the quarter, compared to analysts' expectations of $1.30 million. As a group, analysts anticipate that Senti Biosciences, Inc. will post -14.54 EPS for the current year.
Hedge Funds Weigh In On Senti Biosciences
Institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC bought a new position in shares of Senti Biosciences in the 4th quarter worth $181,000. Virtu Financial LLC bought a new position in shares of Senti Biosciences during the 4th quarter valued at $47,000. Nantahala Capital Management LLC bought a new position in shares of Senti Biosciences during the 1st quarter valued at $2,984,000. Finally, Heights Capital Management Inc. bought a new position in shares of Senti Biosciences during the 1st quarter valued at $2,520,000. Institutional investors own 25.73% of the company's stock.
Senti Biosciences Company Profile
(
Get Free Report)
Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.
Featured Articles
Before you consider Senti Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Senti Biosciences wasn't on the list.
While Senti Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
